Lau, Cedric http://orcid.org/0000-0001-5062-9331
Mohmaed Ali, Ma Ida http://orcid.org/0000-0002-6853-6763
Lin, Lishi http://orcid.org/0000-0002-9733-7720
van Balen, Dorieke E. M.
Jacobs, Bart A. W. http://orcid.org/0009-0002-5455-4431
Nuijen, Bastiaan
Smeenk, Robert M.
Steeghs, Neeltje http://orcid.org/0000-0003-2989-2279
Huitema, Alwin D. R. http://orcid.org/0000-0003-1939-4639
Article History
Received: 9 November 2023
Accepted: 19 January 2024
First Online: 1 March 2024
Declarations
:
: N Steeghs provided consultation or attended advisory boards for Boehringer Ingelheim, Ellipses Pharma, GlaxoSmithKline, Incyte, Luszana. N Steeghs received research grants from Abbvie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Cantargia, CellCentric, Cogent Biosciences, Cresecendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GlaxoSmithKline, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Lixte, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, Takeda. All outside the submitted work, all payment to the Netherlands Cancer Institute.On behalf of all the other authors, the corresponding author states that there is no conflict of interest.
: All the authors declare that there is no conflict of interest related to this work.Research involving human participants.The conduct of this observational study was approved by the Investigational Review Board of the NKI (IRBd23-007).
: All subjects provided informed consent for use of their data.